


Washington State Life Science Investment Report December 2023

A monthly report summarizing life science transactions in Washington State.


BY THE NUMBERS: **35** TRANSACTIONS TOTALING OVER **\$855M**
(YTD)



Deals Per Sector



Disclosed Funding By Sector



DECEMBER TOP TRANSACTIONS

Parse Biosciences announced it has closed a total of \$50M in financing from a Series C equity raise and the closing of a debt facility. Soleus Capital led the Series C equity financing, which included participation by new and current investors including Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital ([BusinessWire](#)).

Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has announced the closing of a major fundraising round led by BroadOak Capital Partners. The oversubscribed funding round also featured participation from existing investors and key opinion leaders across the life sciences industry ([Pluristyx](#)).

*Pending transactions noted here are included in financial data only upon closing.

OTHER TRENDS & HIGHLIGHTS

Icosavax, Seattle-based a spin-out from the University of Washington's Institute for Protein Design, will be acquired by biotech giant AstraZeneca for up to \$1.1B. Founded in 2017, Icosavax is developing vaccines that resemble naturally occurring viruses. Its lead product targets respiratory viruses ([GeekWire](#)).

Bristol Myers Squibb announced that it signed an exclusive license and collaboration agreement with SystImmune to develop the biotech's investigational bi-specific antibody-drug conjugate BL-B01D1 as a treatment for solid tumors. Under the agreement, BMS will make an upfront payment of \$800M and pledge up to \$500M in contingent near-term payments ([BioSpace](#)).

Pfizer Completes \$43B Acquisition of Seagen. It has become the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for \$63B in 2019. The buyout of the antibody-drug conjugate (ADC) specialist has doubled Pfizer's pipeline to 60 programs ([FiercePharma](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
14-Dec-2023	Parse Biosciences	Biotech	Series C	\$26,125,000	Seattle
14-Dec-2023	Parse Biosciences	Biotech	Debt	\$23,875,000	Seattle
21-Dec-2023	Pluristyx, Inc	Biotech	Venture	N/A	Seattle
Disclosed transactions monthly totals:					
				December Total:	\$50,000,000
				November Total:	<u>\$12,680,000</u>
				October Total:	<u>\$207,800,000</u>
				September Total:	<u>\$8,000,000</u>
				August Total:	<u>\$118,790,000</u>
				July Total:	<u>\$111,150,000</u>
				June Total:	<u>\$210,900,000</u>
				May Total:	<u>\$18,500,000</u>
				April Total:	<u>\$5,000,000</u>
				March Total:	<u>\$33,000,000</u>
				February Total:	<u>\$30,440,000</u>
				January Total:	<u>\$48,000,000</u>